Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX788 + Pyrotinib vs TCBHP in Neoadjuvant HER2+ Breast Cancer
NCT05426486Phase 3Active, not recruiting
- Start
- May 2022
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Antibody-Drug Conjugates (ADCs), Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of anvatabart opadotin, pyrotinib in breast cancer. Started May 2022; status: active, not recruiting.
02
Drugs
anvatabart opadotinpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05426486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05426486.